HyperAldosteronism in Pregnancy Predicted Impacts (H.A.P.P.I. Trial)

Condition(s) studied

Investigational drug(s) / intervention(s)

Aldosterone/Renin Ratio: Blood sample collected to measure the aldosterone/renin ratio for the primary hyperaldosteronism screening.

Study summary

Primary hyperaldosteronism confers a higher risk of cardiovascular complications compared to essential hypertension. Preliminary data is controversial in regards of excessive maternal fetal and neonatal excessive risks in pregnancy.

This study aims at establishing the prevalence of PHA in an population with a recent episode of hypertensive disorder of pregnancy (HDP). The goal is to determine if a universal screening for PHA after a HDP is worthed. The investigators also wish to evaluate the complication rate in pregnant women with PHA compared to women without PHA.

This is a prospective cohort study where all eligible women will be screened for PHA after a HDP episode in the last pregnancy. We will then compare PHA women to non PHA women according to pregnancy complications.

Eligibility

Primary outcome measure(s)

• Primary hyperaldosteronism (PHA) prevalence in pregnant women with hypertensive disorders of pregnancy. — Screening done between 4 and 24 weeks post-partum
  Prevalence of PHA in women with a hypertensive disorder of pregnancy in last pregnancy

Trial sites (2)

More Université de Sherbrooke trials in Canada

Other trials for the same condition